Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 26 September 2019, 13:21 HKT/SGT
Share:
    

Source: Eisai
Eisai and Tokio Marine Nichido Enter Into Business Alliance for Co-Existence and Prevention of Dementia

TOKYO, Sept 26, 2019 - (JCN Newswire) - Eisai Co., Ltd. and Tokio Marine & Nichido Fire Insurance Co., Ltd. announced today that the companies have entered into a business alliance agreement for co-existence and prevention of dementia.

Under this agreement, the following initiatives are scheduled: (1) "disease awareness initiatives" to dispel the misunderstandings and assumptions and to attempt for a widespread correct understanding of dementia, (2) "environment development" to implement the self-assessment of cognitive function on a daily basis, and (3) "measures to familiarize insurance product" to support people with dementia so they can continue to live their own lives. Eisai and Tokio Marine Nichido will work towards co-existence and prevention of dementia by mutually utilizing Eisai's abundant experience and knowledge of medicine creation and disease awareness activities in the field of dementia as well as Tokio Marine Nichido's expertise and networks cultivated in its insurance products and related services.

As part of dementia disease awareness activities, Eisai and Tokio Marine Nichido today began distribution of the booklet "Wakaru to Kawaru Ninchisho - What is Dementia?" that was co-produced based on Eisai's dementia experience and expertise.

This booklet simply summarizes the symptoms and types of dementia and progression of Alzheimer's disease. In addition, it includes interviews with specialists and medical staff about the images of dementia and the daily life of patients and their families living with dementia.

"Misunderstandings and assumptions, such as people with dementia can't understand anything or they are not themselves once they devlop dementia, create the impression that dementia is terrible and misery. I hope this booklet will help educate people about the the reality of dementia by prodiving accurate information and dispelling misperceptions," said Dr. Manabu Ikeda, Professor, Department of Psychiatry, Osaka University Medical School, who supervised this booklet.

The booklet for dementia disease awareness will be serialized and issued continuously.

With the rapid aging of the population, it is predicted that one out of five elderly people over the age of 65 will have dementia in Japan. The "Outline for Promoting the Dementia Plan" was compiled by the government in June this year. The dementia barrier-free efforts are aimed at co-existence so that those with dementia can continue living the way they want in the communities they are used to living. The initiatives for prevention based on the co- existence foundation are expected to make significant progress.

Eisai and Tokio Marine Nichido will collaborate on initiatives for co-existence and prevention of dementia, including dementia disease awareness initiatives. The copmanies aim to contribute to the realization of the well-being of people with dementia and their families by considering collaboration with other companies and organizations that agree with the purpose of Eisai and Tokio Marine Nichido.

About Tokio Marine & Nichido Fire Insurance Co., Ltd.

Tokio Marine & Nichido Fire Insurance Co., Ltd. has provided a variety of insurance products and the related services to support the challenges of all individual and corporate customers. In the field of dementia, we are advancing initiatives such as development and launch of the industry's first "Ninchisho Anshin Plan" which is an exclusive insurance for people with dementia and their families.

We will also utilize technologies to further enhance the "power of insurance" and promote its penetration "wholeheartedly" as we strive to support people and corporations that take on challenges, thereby contributing to resolving social issues in Japan.

For further information on Tokio Marine & Nichido Fire Insurance Co., Ltd., please visit https://www.tokiomarine- nichido.co.jp.


Contact:
Media Inquiries:
Eisai Co., Ltd.
Public Relations Department 
TEL: +81-(0)3-3817-5120


Topic: Press release summary
Source: Eisai

Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Nov 20, 2024 10:51 HKT/SGT
Rozebalamin for Injection 25mg (Mecobalamin) for Amyotrophic Lateral Sclerosis Launched in Japan
Nov 20, 2024 09:24 HKT/SGT
Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract Cancer with FGFR2 Gene Fusion or Rearrangements
Nov 15, 2024 16:33 HKT/SGT
Nationwide TV Commercial Launched in Japan to Raise Awareness About MCI (Mild Cognitive Impairment)
Nov 15, 2024 13:31 HKT/SGT
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease
Nov 5, 2024 10:35 HKT/SGT
Eisai's Corporate Venture Capital Subsidiary, Eisai Innovation, Inc., Selected for AMED's 'Strengthening Program for Pharmaceutical Startup Ecosystem"
Nov 1, 2024 12:56 HKT/SGT
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status
Oct 31, 2024 12:56 HKT/SGT
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer's Disease (CTAD) Conference
Oct 31, 2024 10:33 HKT/SGT
Eisai Presents Latest Clinical Findings Suggesting Inhibition of Tau Propagation by Anti-MTBR Tau Antibody E2814 at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)
Oct 17, 2024 19:01 HKT/SGT
A Joint Regional Cohort Study by Shimadzu, Eisai, Oita University, and Usuki City Medical Association
Oct 17, 2024 14:59 HKT/SGT
Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in Australia
More news >>
 News Alerts
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: